InnoCan Pharma Corporation (INNO.CN)
| Previous Close | 0.3350 |
| Open | 0.3150 |
| Bid | 0.3350 x N/A |
| Ask | 0.3400 x N/A |
| Day's Range | 0.3150 - 0.3400 |
| 52 Week Range | 0.1800 - 0.5200 |
| Volume | |
| Avg. Volume | 111,528 |
| Market Cap | 89.234M |
| Beta (5Y Monthly) | 3.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireInnocan Pharma Announces Brokered LIFE Offering of Units for Up to $3 Million
NOT FOR DISSEMINATION IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HERZLIYA, Israel and CALGARY, Alberta, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Innocan Pharma Corporation (the “Company”) (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has entered into an agreement with Research Capital Corporation as the sole agent and sole bookrunner (the “Agent”) on a “best efforts” agency basis in connection with a marketed private placement offering (the “Offer
CNW GroupInnocan Pharma Announces the Addition of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Advisory Board
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pioneering pharmaceutical technology company specializing in innovative wellness products, is elated to announce the appointment of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Scientific Advisory Board (SAB). Dr. Pergolizzi, a distinguished expert in the field of pain management and critical care medicine, will be instrumental in the Company's upcoming planned FDA filing for human medications.
CNW GroupInnocan Pharma Announces Promising Results from Hair Care Cream Efficacy Test
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative wellness products, announced today the successful results of a controlled efficacy test (the "Trial") regarding its hair care cream (the "Product").
